Wuhan YZY Biopharma Co (HKSE:02496) EPS (Basic): HK$-0.48 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Wuhan YZY Biopharma Co EPS (Basic)?

Wuhan YZY Biopharma Co HKSE:02496 EPS (Basic) is HK$-0.48 as of Dec. 2025. The stock has 8 warning signs investors should review.

Wuhan YZY Biopharma Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.48.

Wuhan YZY Biopharma Co's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.48.

Wuhan YZY Biopharma Co's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.16. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.48.

During the past 3 years, the average EPS without NRI Growth Rate was 23.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Wuhan YZY Biopharma Co's highest 3-Year average EPS without NRI Growth Rate was 23.80% per year. The lowest was 17.40% per year. And the median was 20.60% per year.

Wuhan YZY Biopharma Co  (HKSE:02496) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Wuhan YZY Biopharma Co EPS (Basic) Related Terms

Wuhan YZY Biopharma Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Wuhan YZY Biopharma Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co EPS (Basic) Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-0.94 -1.09 -1.14 -0.53 -0.49

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial -0.59 -0.43 -0.11 -0.33 -0.16

Wuhan YZY Biopharma Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Wuhan YZY Biopharma Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-93.606-0)/193.849
=-0.48

Wuhan YZY Biopharma Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-28.61-0)/193.849
=-0.15

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.48 mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a EPS (Basic) of HK$-0.48 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's EPS (Basic) too high?
Wuhan YZY Biopharma Co's current EPS (Basic) is HK$-0.48.
How does Wuhan YZY Biopharma Co's EPS (Basic) compare to VRTX and REGN?
Wuhan YZY Biopharma Co's EPS (Basic) of HK$-0.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current EPS (Basic) is HK$-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current EPS (Basic) of HK$-0.48. The current EPS (Basic) is HK$-0.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current EPS (Basic) is HK$-0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan YZY Biopharma Co Business Description

Address No. 666 Gaoxin Road, Building C2-1, Optics Valley Bio-City, East Lake High Tech Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.